M. Kresken

发表

Antimicrobial susceptibility and molecular epidemiology of Neisseria gonorrhoeae in Germany.

T. Wichelhaus, S. Göttig, N. Horn, 2014, International journal of medical microbiology : IJMM.

Increasing incidence and widespread dissemination of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals in central Europe, with special reference to German hospitals.

W. Witte, M. Kresken, C. Cuny, 1997, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992-1994.

R. Lütticken, A. Queck, M. Kresken, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose

F. Sörgel, K. Naber, M. Kinzig-Schippers, 1997, Infection.

[Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich Society for Chemotherapy].

F. Sörgel, H. Wacha, H. Lode, 2002, Medizinische Monatsschrift fur Pharmazeuten.

High Prevalence of the ermB Gene among Erythromycin-Resistant Streptococcus pneumoniae Isolates in Germany during the Winter of 2000-2001 and In Vitro Activity of Telithromycin

M. Kresken, B. Wiedemann, B. Henrichfreise, 2004, Antimicrobial Agents and Chemotherapy.

Performance of the Etest for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa toward Ceftazidime-Avibactam

M. Kresken, B. Körber-Irrgang, 2018, Journal of Clinical Microbiology.

The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia

X. Daura, S. Niemann, U. Schaible, 2020, Nature Communications.

Thirty years of VRE in Germany - "expect the unexpected": The view from the National Reference Centre for Staphylococci and Enterococci.

J. Bender, G. Werner, M. Kresken, 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Comment of an Expert Group of the Paul-Ehrlich-Society for Chemotherapy on the benefit assessment of fidaxomicin for treatment of Clostridium difficile infections

A. Hoerauf, Mathias W Pletz, E. Reisinger, 2013 .

of Telithromycin Activity the Winter of 2000-2001 and In Vitro Isolates in Germany during pneumoniae Streptococcus Erythromycin-Resistant Gene among ermB High Prevalence of the

M. Kresken, B. Wiedemann, B. Henrichfreise, 2014 .

Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001.

T. Wichelhaus, F. Schmitz, M. Kresken, 2004, International journal of antimicrobial agents.

Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20

G. Werner, F. Wagenlehner, Y. Pfeifer, 2022, Antibiotics.

In vitro activity of ceftobiprole against key pathogens associated with pneumonia in hospitalized patients: results from the PEG surveillance study, 2010

G. Werner, Y. Pfeifer, M. Kaase, 2015 .

Nationwide German Multicenter Study on the Prevalence of Antibiotic Resistance in Streptococcal Blood Isolates from Neutropenic Patients and Comparative In Vitro Activities of Quinupristin-Dalfopristin and Eight Other Antimicrobials

R. Lütticken, G. Peters, H. Schorn, 2001, Journal of Clinical Microbiology.

Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005-2009).

P. Higgins, H. Seifert, H. Wisplinghoff, 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Activities of various β‐lactams and β‐lactam/β‐lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains

A. Rodloff, H. Seifert, U. Frank, 2005 .

Comparative activity of pradofloxacin and marbofloxacin against coagulase-positive staphylococci in a pharmacokinetic-pharmacodynamic model based on canine pharmacokinetics.

M. Kresken, B. Körber-Irrgang, D. Hafner, 2012, Journal of veterinary pharmacology and therapeutics.

Evaluation of a novel optical assay for rapid detection of methicillin-resistant Staphylococcus aureus in liquid culture.

E. Idelevich, K. Becker, D. Knaack, 2018, Journal of microbiological methods.

Nationwide German Multicenter Study on Prevalence of Antibiotic Resistance in Staphylococcal Bloodstream Isolates and Comparative In Vitro Activities of Quinupristin-Dalfopristin

G. Peters, C. von Eiff, M. Kresken, 2000, Journal of Clinical Microbiology.

Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains.

A. Rodloff, H. Seifert, U. Frank, 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.

H. Seifert, S. Gatermann, N. Pfennigwerth, 2020, International journal of antimicrobial agents.

In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany.

H. Seifert, S. Gatermann, N. Pfennigwerth, 2020, International journal of antimicrobial agents.

In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistantStreptococcus pneumoniae

R. Lütticken, M. Kresken, R. Reinert, 1998, European Journal of Clinical Microbiology and Infectious Diseases.

Surveillance of linezolid resistance in Germany, 2001-2002.

M. Kresken, D. Hafner, P. Shah, 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin

M. Kresken, B. Wiedemann, 1988, Antimicrobial Agents and Chemotherapy.

The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia

X. Daura, S. Niemann, U. Schaible, 2019, Nature Communications.

[In-vitro activity of mecillinam against urine isolates of Escherichia coli from outpatient departments in Germany].

K. Naber, M. Kresken, B. Körber-Irrgang, 2017, Aktuelle Urologie.

The epidemiology of β-lactamases

M. Kresken, B. Wiedemann, C. Kliebe, 1989 .

Development of resistance in the past decade in central Europe.

M. Kresken, B. Wiedemann, 1986, The Journal of antimicrobial chemotherapy.

Whole genome analyses of CMY-2-producing Escherichia coli isolates from humans, animals and food in Germany

L. Kreienbrock, S. Fuchs, T. Eckmanns, 2018, BMC Genomics.

In vitro activity of daptomycin combined with other antimicrobial agents against Gram-negative bacteria

M. Kresken, B. Körber-Irrgang, 2010 .

Antibiotic resistance in pulmonary infections: mechanisms and epidemiology

Mathias W Pletz, R. Ehricht, O. Makarewicz, 2017 .

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.

P. Higgins, H. Seifert, M. Kresken, 2020, The Journal of antimicrobial chemotherapy.

Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales

A. van Belkum, G. Zambardi, C. Emery, 2021, Journal of clinical microbiology.

Changing Pattern of Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus From German Hospitals

W. Witte, M. Kresken, C. Cuny, 2001, Infection Control & Hospital Epidemiology.

In Vitro Spectrum of Activity of Finafloxacin, a Novel, pH-Activated Fluoroquinolone, under Standard and Acidic Conditions

F. Goh, H. Labischinski, R. Endermann, 2011, Antimicrobial Agents and Chemotherapy.

Pefloxacin single-dose in the treatment of acute uncomplicated lower urinary tract infections in women: a meta-analysis of seven clinical trials.

K. Naber, M. Kresken, W. Baurecht, 1994, International journal of antimicrobial agents.

Urinary Concentrations and Antibacterial Activities of Nitroxoline at 250 Milligrams versus Trimethoprim at 200 Milligrams against Uropathogens in Healthy Volunteers

W. Pfister, K. Naber, F. Wagenlehner, 2013, Antimicrobial Agents and Chemotherapy.

Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.

I. Morrissey, H. Weiher, M. Kresken, 2007, International Journal of Antimicrobial Agents.

Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany

E. Leitner, H. Seifert, K. Becker, 2011, European Journal of Clinical Microbiology & Infectious Diseases.

Antibiotika-Verbrauchs-Surveillance

T. Eckmanns, M. Fellhauer, W. Kern, 2013, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany.

G. Werner, Y. Pfeifer, M. Kresken, 2022, Journal of Antimicrobial Chemotherapy.

Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975–1995

M. Kresken, D. Hafner, the Study Group Bacterial Resistance of the Paul-Ehrli Chemotherapy, 2007, Infection.

S2k guideline “Calculated parenteral initial treatment of bacterial infections in adults – update 2018”, 2nd updated version: Foreword

B. Grabein, M. Kresken, K. Bodmann, 2020, GMS infectious diseases.

Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries.

H. Seifert, H. Wisplinghoff, Á. Pascual, 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany

E. Leitner, H. Seifert, E. Halle, 2008, European Journal of Clinical Microbiology & Infectious Diseases.

Effect of pH on the In Vitro Activity of Finafloxacin against Gram-negative and Gram-positive Bacteria

M. Kresken, 2008 .

Temporal trends of the in vitro activity of tigecycline and comparator antibiotics against clinical aerobic bacterial isolates collected in Germany, 2006–2014: results of the Tigecycline Evaluation and Surveillance Trial (TEST)

A. Rodloff, H. Seifert, K. Becker, 2016, GMS infectious diseases.

Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007)

E. Leitner, H. Seifert, G. Peters, 2009, European Journal of Clinical Microbiology & Infectious Diseases.

Multicenter Clinical Evaluation of ETEST Eravacycline for Susceptibility Testing of Enterobacteriaceae and Enterococci

G. Zambardi, C. Emery, M. Kresken, 2023, Journal of clinical microbiology.

Calculated parenteral initial treatment of bacterial infections: Microbiology

T. Wichelhaus, K. Becker, E. Straube, 2020, GMS infectious diseases.

Kalkulierte parenterale Initialtherapie bakterieller Infektionen: Mikrobiologie

T. Wichelhaus, K. Becker, E. Straube, 2020 .

[Multiresistant pathogens--a challenge for clinicians].

H. Lode, R. Stahlmann, M. Kresken, 2013, Zentralblatt fur Chirurgie.

[S2k guidelines of the PEG on calculated parenteral initial treatment of bacterial diseases in adults : Focussed summary and supplementary information on antibiotic treatment of critically ill patients].

T. Brenner, B. Grabein, M. Kresken, 2018, Der Anaesthesist.

In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.

M. Kresken, B. Körber-Irrgang, T. Davies, 2011, International journal of antimicrobial agents.

The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany, 2010-2019.

U. Göbel, A. Mellmann, T. Wichelhaus, 2022, International journal of antimicrobial agents.

Antimicrobial susceptibility of bacterial isolates from patients presenting with ear, nose and throat (ENT) infections in the German community healthcare setting

M. Havel, B. Olzowy, M. Kresken, 2017, European Journal of Clinical Microbiology & Infectious Diseases.

[Surveillance of antibiotic consumption : clarification of the "definition of data on the nature and extent of antibiotic consumption in hospitals according to § 23 paragraph 4 sentence 2 of the IfSG"].

T. Eckmanns, K. de With, M. Fellhauer, 2013, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.

Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and Enterococcus faecium

G. Werner, M. Kresken, F. Layer, 2021, Antibiotics.

Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in Pseudomonas aeruginosa: Validation in a Multicenter German Cohort.

H. Seifert, D. Nicolau, M. Kresken, 2021, Microbial drug resistance.

In Vitro Activity of Nitroxoline against Escherichia coli Urine Isolates from Outpatient Departments in Germany

M. Kresken, B. Körber-Irrgang, 2014, Antimicrobial Agents and Chemotherapy.

Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum β-lactamases and the role of fosfomycin.

Y. Pfeifer, M. Kresken, B. Körber-Irrgang, 2014, International journal of antimicrobial agents.

In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17

P. Higgins, S. Gatermann, N. Pfennigwerth, 2023, Antibiotics.

In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.

H. Seifert, M. Kresken, B. Körber-Irrgang, 2017, International journal of antimicrobial agents.

Activity of temocillin against CTX-M-producing Escherichia coli and Klebsiella pneumoniae from Germany.

G. Werner, Y. Pfeifer, M. Kresken, 2018, International journal of antimicrobial agents.

The pharmacokinetics of ticarcillin/clavulanate acid in neonates.

M. Kresken, D. Hafner, R. Horton, 1989, The Journal of antimicrobial chemotherapy.

Escherichia coli ST1421 harbouring the hybrid extended-spectrum β-lactamase CTX-M-64 from a German patient.

G. Werner, D. Jonas, Y. Pfeifer, 2018, Journal of global antimicrobial resistance.

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates

P. Higgins, M. Kresken, D. Stefanik, 2023, Antibiotics.

Prevalence of fluoroquinolone resistance in Europe

S. Esposito, H. Mittermayer, D. Reeves, 1994, Infection.

Calculated parenteral initial treatment of bacterial infections: Introduction and antibiotics

M. Wilke, P. Dohmen, B. Grabein, 2020, GMS infectious diseases.

Temocillin susceptibility in Enterobacterales with an ESBL/AmpC-phenotype.

G. Werner, Y. Pfeifer, M. Kresken, 2020, International journal of antimicrobial agents.

Performance of the Etest for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa toward Ceftazidime-Avibactam

M. Kresken, B. Körber-Irrgang, 2018, Journal of Clinical Microbiology.

German multicentre study on the in vitro susceptibility of Bacteroides species. The German Bacteroides Study Group.

A. Rodloff, M. Kresken, A. Jansen, 1992, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

German multicentre study on the in vitro susceptibility ofBacteroides species

A. Rodloff, M. Kresken, the French Study Group, 2005, European Journal of Clinical Microbiology and Infectious Diseases.